204 related articles for article (PubMed ID: 11170504)
1. DNA topoisomerase II inhibition by peroxisomicine A(1) and its radical metabolite induces apoptotic cell death of HL-60 and HL-60/MX2 human leukemia cells.
Lansiaux A; Laine W; Baldeyrou B; Mahieu C; Wattez N; Vezin H; Martinez FJ; Piñeyro A; Bailly C
Chem Res Toxicol; 2001 Jan; 14(1):16-24. PubMed ID: 11170504
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: relation to drug-induced apoptosis.
Dassonneville L; Lansiaux A; Wattelet A; Wattez N; Mahieu C; Van Miert S; Pieters L; Bailly C
Eur J Pharmacol; 2000 Dec; 409(1):9-18. PubMed ID: 11099695
[TBL] [Abstract][Full Text] [Related]
3. Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II.
Xue X; Qu XJ; Gao ZH; Sun CC; Liu HP; Zhao CR; Cheng YN; Lou HX
Invest New Drugs; 2012 Feb; 30(1):212-22. PubMed ID: 20924640
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of topoisomerase II by the marine alkaloid ascididemin and induction of apoptosis in leukemia cells.
Dassonneville L; Wattez N; Baldeyrou B; Mahieu C; Lansiaux A; Banaigs B; Bonnard I; Bailly C
Biochem Pharmacol; 2000 Aug; 60(4):527-37. PubMed ID: 10874127
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform.
Harker WG; Slade DL; Drake FH; Parr RL
Biochemistry; 1991 Oct; 30(41):9953-61. PubMed ID: 1655025
[TBL] [Abstract][Full Text] [Related]
6. Apoptotic response of HL-60 human leukemia cells to the antitumor drug NB-506, a glycosylated indolocarbazole inhibitor of topoisomerase 1.
Facompre M; Goossens JF; Bailly C
Biochem Pharmacol; 2001 Feb; 61(3):299-310. PubMed ID: 11172734
[TBL] [Abstract][Full Text] [Related]
7. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells.
Boland MP; Fitzgerald KA; O'Neill LA
J Biol Chem; 2000 Aug; 275(33):25231-8. PubMed ID: 10940316
[TBL] [Abstract][Full Text] [Related]
9. Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin.
Huang X; Okafuji M; Traganos F; Luther E; Holden E; Darzynkiewicz Z
Cytometry A; 2004 Apr; 58(2):99-110. PubMed ID: 15057963
[TBL] [Abstract][Full Text] [Related]
10. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone.
Harker WG; Slade DL; Parr RL; Holguin MH
Cancer Res; 1995 Nov; 55(21):4962-71. PubMed ID: 7585537
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity and cell cycle effects of novel indolo[2,3-b]quinoline derivatives.
Humeniuk R; Kaczmarek L; Peczyńska-Czoch W; Marcinkowska E
Oncol Res; 2003; 13(5):269-77. PubMed ID: 12688678
[TBL] [Abstract][Full Text] [Related]
12. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide.
Mizutani H; Tada-Oikawa S; Hiraku Y; Kojima M; Kawanishi S
Life Sci; 2005 Feb; 76(13):1439-53. PubMed ID: 15680309
[TBL] [Abstract][Full Text] [Related]
14. Quercetin simultaneously induces G
Chang JL; Chow JM; Chang JH; Wen YC; Lin YW; Yang SF; Lee WJ; Chien MH
Environ Toxicol; 2017 Jul; 32(7):1857-1868. PubMed ID: 28251795
[TBL] [Abstract][Full Text] [Related]
15. DNA damage induced by DNA topoisomerase I- and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis.
Huang X; Traganos F; Darzynkiewicz Z
Cell Cycle; 2003; 2(6):614-9. PubMed ID: 14504478
[TBL] [Abstract][Full Text] [Related]
16. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC
Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224
[TBL] [Abstract][Full Text] [Related]
17. Relationships between DNA strand breakage and apoptotic progression upon treatment of HL-60 leukemia cells with tafluposide or etoposide.
Kluza J; Mazinghien R; Irwin H; Hartley JA; Bailly C
Anticancer Drugs; 2006 Feb; 17(2):155-64. PubMed ID: 16428933
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells.
Ibrado AM; Huang Y; Fang G; Liu L; Bhalla K
Cancer Res; 1996 Oct; 56(20):4743-8. PubMed ID: 8840993
[TBL] [Abstract][Full Text] [Related]
19. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
20. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Ellis AL; Nowak B; Plunkett W; Zwelling LA
Cancer Chemother Pharmacol; 1994; 34(3):249-56. PubMed ID: 8004759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
